Search Results

Proepileptic phenotype of SV2A-deficient mice is associated with reduced anticonvulsant efficacy of levetiracetam

Authors: Kaminski, Rafal M.; Gillard, Michel; Leclercq, Karine; Hanon, Etienne; Lorent, Geneviève; Dassesse, Donald; Matagne, Alain; Klitgaard, Henrik

Source: Epilepsia, Volume 50, Number 7, July 2009 , pp. 1729-1740(12)

Publisher: Blackwell Publishing

Pilot study to evaluate the efficacy and tolerability of levetiracetam (Keppra^®) in treatment of patients with trigeminal neuralgia

Authors: Jorns, T. P.; Johnston, A.; Zakrzewska, J. M.

Source: European Journal of Neurology, Volume 16, Number 6, June 2009 , pp. 740-744(5)

Publisher: Blackwell Publishing

Seletracetam (ucb 44212) inhibits high-voltage-activated Ca²⁺ currents and intracellular Ca²⁺ increase in rat cortical neurons in vitro

Authors: Martella, Giuseppina; Bonsi, Paola; Sciamanna, Giuseppe; Platania, Paola; Madeo, Graziella; Tassone, Annalisa; Cuomo, Dario; Pisani, Antonio

Source: Epilepsia, Volume 50, Number 4, April 2009 , pp. 702-710(9)

Publisher: Blackwell Publishing

Benefit of combination therapy in epilepsy: A review of the preclinical evidence with levetiracetam

Authors: Kaminski, Rafal M.; Matagne, Alain; Patsalos, Philip N.; Klitgaard, Henrik

Source: Epilepsia, Volume 50, Number 3, March 2009 , pp. 387-397(11)

Publisher: Blackwell Publishing

Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in Chinese patients with refractory partial-onset seizures

Authors: Wu, Xun-Yi; Hong, Zhen; Wu, Xun; Wu, Li-Wen; Wang, Xue-Feng; Zhou, Dong; Zhao, Zhong-Xin; Lv, Chuan-Zhen

Source: Epilepsia, Volume 50, Number 3, March 2009 , pp. 398-405(8)

Publisher: Blackwell Publishing

Decreased expression of synaptic vesicle protein 2A, the binding site for levetiracetam, during epileptogenesis and chronic epilepsy

Authors: van Vliet, Erwin A.; Aronica, Eleonora; Redeker, Sandra; Boer, Karin; Gorter, Jan A.

Source: Epilepsia, Volume 50, Number 3, March 2009 , pp. 422-433(12)

Publisher: Blackwell Publishing

Development of tolerance to levetiracetam in rats with chronic epilepsy

Authors: van Vliet, Erwin A.; van Schaik, Rosalinda; Edelbroek, Peter M.; Lopes da Silva, Fernando H.; Wadman, Wytse J.; Gorter, Jan A.

Source: Epilepsia, Volume 49, Number 7, July 2008 , pp. 1151-1159(9)

Publisher: Blackwell Publishing

Levetiracetam: the first SV2A ligand for the treatment of epilepsy

Authors: Klitgaard, Henrik; Verdru, Peter

Source: Expert Opinion on Drug Discovery, Volume 2, Number 11, November 2007 , pp. 1537-1545(9)

Publisher: Informa Healthcare

Retrospective analysis of the efficacy and tolerability of levetiracetam in patients with metastatic brain tumors

Authors: Newton, Herbert; Dalton, Jennifer; Goldlust, Samuel; Pearl, Dennis

Source: Journal of Neuro-Oncology, Volume 84, Number 3, September 2007 , pp. 293-296(4)

Publisher: Springer

The safety of levetiracetam

Authors: Sirsi, Deepa; Safdieh, Joseph E

Source: Expert Opinion on Drug Safety, Volume 6, Number 3, May 2007 , pp. 241-250(10)

Publisher: Informa Healthcare

Single-dose pharmacokinetics of levetiracetam in healthy Chinese male subjects

Authors: Zhao, Qian; Jiang, Ji; Li, XiaoMing; Lu, Zhihong (Sarah); Hu, Pei

Source: British Journal of Clinical Pharmacology, Volume 63, Number 5, May 2007 , pp. 614-617(4)

Publisher: Blackwell Publishing

Levetiracetam [Keppra; UCB] has been approved by the European Commission for the treatment of partial onset seizures

Source: Inpharma, Volume 1, Number 1552, 2006-08-26 , pp. 23-23(1)

Publisher: Adis International

Levetiracetam: past, present and future

Authors: Safdieh, Joseph E; Harden, Cynthia L

Source: Future Neurology, Volume 1, Number 4, July 2006 , pp. 365-371(7)

Publisher: Future Medicine

Retrospective analysis of the efficacy and tolerability of levetiracetam in brain tumor patients

Authors: Newton, Herbert; Goldlust, Samuel; Pearl, Dennis

Source: Journal of Neuro-Oncology, Volume 78, Number 1, May 2006 , pp. 99-102(4)

Publisher: Springer

Levetiracetam: an innovative and cost-effective add-on drug for refractory partial epilepsy

Authors: Lorier, Jacques Le; Godfroid, Philippe; Hart, Yvonne; Roberts, Richard

Source: Expert Review of Pharmacoeconomics and Outcomes Research, Volume 4, Number 2, April 2004 , pp. 143-151(9)

Publisher: Expert Reviews

Side Effects of Antiepileptics— A Review

Authors: Kulbir S. Walia; Elizabeth A. Khan; Dong H. Ko; Shariq S. Raza; Yasin N. Khan

Source: Pain Practice, Volume 4, Number 3, September 2004 , pp. 194-203(10)

Publisher: Blackwell Publishing

Efficacy and Safety of Levetiracetam in Pediatric Migraine

Author: Miller G.S.

Source: Headache: The Journal of Head and Face Pain, Volume 44, Number 3, March 2004 , pp. 238-243(6)

Publisher: Blackwell Publishing

Levetiracetam, a New Antiepileptic Agent: Lack of In Vitro and In Vivo Pharmacokinetic Interaction with Valproic Acid

Authors: Coupez, René; Nicolas, Jean-Marie; Browne, Thomas R.

Source: Epilepsia, Volume 44, Number 2, February 2003 , pp. 171-178(8)

Publisher: Blackwell Publishing

Use of levetiracetam in a population of patients aged 65 years and older: a subset analysis of the KEEPER trial

Authors: Ferrendelli J.A.; French J.; Leppik I.; Morrell M.J.; Herbeuval A.; Han J.; Magnus L.

Source: Epilepsy & Behavior, Volume 4, Number 6, December 2003 , pp. 702-709(8)

Publisher: Elsevier

Anxiolytic effects of the novel anti-epileptic drug levetiracetam in the elevated plus-maze test in the rat

Authors: Gower A.J.; Falter U.; Lamberty Y.

Source: European Journal of Pharmacology, Volume 481, Number 1, 14 November 2003 , pp. 67-74(8)

Publisher: Elsevier